Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop fordry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

Health Care

Health Diagnostics

Therapeutics

Cambium Medical Technologies

Terence A. Walts

Tina W. McKeon

Clayton W. Coley

Neera Jagirdar

Michael Broughton

Dennis E. Hannigan

John D. Roback

Edmund K. Waller

The Legal and Regulatory Affairs Team at Cambium Medical Technologies ensures compliance with all relevant laws and regulations, manages intellectual property matters, oversees clinical trial approvals, and supports the commercialization of regenerative therapies like Elate Ocular. This team works to navigate FDA regulations, secure patents, and maintain the highest quality standards to bring innovative medical solutions to market.

Legal and Regulatory Affairs Team

Medical Advisory Team

Leadership Team

Legal and Regulatory Affairs Team

About

Team members

Other teams at Cambium Medical Technologies

Medical Advisory Team

Leadership Team